Last updated on August 2018

Setmelanotide for the Treatment of Early-Onset POMC Deficiency Obesity

Brief description of study

The purpose of the study is to determine the effect of setmelanotide (RM-493) on weight and other factors in patients with pro-opiomelanocortin (POMC) deficiency obesity due to rare bi-allelic loss-of function POMC or PCSK1 genetic mutations.

Clinical Study Identifier: NCT02896192

Contact Investigators or Research Sites near you

Start Over

UZ Gent

Gent, Belgium
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.